Answers are grounded in this paper and cite their sources.
Case series identifies plasma microbial DNA sequencing as a diagnostic tool for toxoplasmosis in high-risk patients, suggesting potential for faster treatment.
From 2017 to 2025, we reviewed plasma microbial cell-free DNA sequencing (mcfDNA NGS) results detecting Toxoplasma gondii. Five patients were identified. Median turnaround was 3 days (2–5). mcfDNA initiated therapy in two and supported empiric treatment in three but required clinical context for interpretation.
No takes yet. Share an insight, caveat, or question.
Centeno et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: